Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial

Table 1 Clinical and biochemical profiles of patients on propranolol or propranolol and spironolactone

Characteristics	Group A n = 17	Group B n = 18	P value
Male:Female ratio	12:5	15:3
Age (yr)	44.3 ± 7.98	46.61 ± 8.71	0.09
Ascites	10	8
Encephalopathy	1	2
Etiology
Alcoholic	6	10
Hepatitis-B	6	2
Hepatitis-C	0	1
Others	5	5
Varices
II	3	4
III	11	9
IV	3	5
Child’s score
A	3	4
B	8	9
C	6	5
Bilirubin (mg/dL)	2.26 ± 1.8	2.13 ± 2.13	0.85
Albumin (mg/dL)	2.89 ± 0.46	2.71 ± 0.78	0.42
Globulin (mg/dL)	3.72 ± 0.76	4.64 ± 2.26	0.12
ALT (IU/L)	79.35 ± 75.43	43.89 ± 18.20	0.08
Urea (mg/dL)	29.53 ± 11.03	28.6 ± 13.57	0.83
Creatinine (mg/dL)	0.88 ± 0.27	0.84 ± 0.28	0.67
Na+ (mEq/L)	135.7 ± 4.9	133.22 ± 4.61	0.13
K+ (mEq/L)	3.74 ± 0.56	3.66 ± 0.49	0.64
Prothrombin time (INR)	1.21 ± 0.16	1.34 ± 0.40	0.30
Dose of propranolol (mg/d)	92.94 ± 23.39	88.89 ± 20.83	0.59

Values are shown as mean ± SE, P < 0.05 considered statistically significant. Group A: Propranolol; Group B: Propranolol and Spironolactone; ALT: Alanine aminotransferase.